

Revenue Strategy Overview

Innovating Growth Across Multiple Verticals

Forward-Looking Statements

These offering materials may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company's management. When used in the offering materials, the words "estimate," "project," "believe," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. These statements reflect management's current views with respect to future events and are subject to risks and uncertainties that could cause the company's actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.


Please note investors in this offering will be clients of the issuer and not Dalmore Group, LLC ("Dalmore"), a registered broker-dealer and member FINRA/SIPC. Dalmore's role in the transaction is to facilitate back-office and regulatory functions related to the Regulation A transaction, and acts only as the broker/dealer of record for the offering listed. Dalmore is not providing investment advice or recommendations, or legal or tax advice.

This Reg A investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. All investors should make their own determination, with the assistance of their own financial or other advisors, as to whether or not to make any investment, based on their own independent evaluation, analysis, and circumstances.

No money or other consideration is being solicited, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement filed by the company with the SEC has been qualified by the SEC. Any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of acceptance given after the date of qualification. An indication of interest involves no obligation or commitment of any kind. An offering statement regarding this offering has been filed with the SEC. You may obtain a copy of the preliminary offering circular that is part of that offering statement. [\[Form 1-A filing with SEC\]](#)

Scaling Across High-Growth Verticals

Our revenue strategy spans five distinct verticals—each targeting high-growth markets with scalable, tech-enabled solutions.




CANNABIS

Precision-grown plants via tissue culture and robotics.



HEMP

High-yield genetics for textiles, fuel, and construction.



ORNAMENTALS

Disease-free decorative plants, scaled through tissue culture.



AGRICULTURE

Boosting soybean & wheat germination across Indian farmland.



EDUCATION

Turning our biotech IP into scalable online learning platform.


Tissue Culture at Scale

Cannabis

This vertical centers on cannabis tissue culture and proprietary genetic development—engineered for precision, consistency, and high-performance yield. With full-scale operations underway, Endless is leveraging biotech to meet rising demand across both medical and adult-use markets.

Endless is redefining scalable cannabis cultivation through disease-free, uniform genetics and closed-loop propagation systems built for global expansion.

- Advanced tissue culture protocols
- AI/ML for environmental control & optimization
- Robotic automation in propagation and harvesting



- EBITDA margin: 25%
- OpEx = 55% of Revenue
- Headcount CAGR: +20% YoY

Revenue
\$60M

EBITDA
\$15M

OpEx
\$33M

Year 1
95 people

Revenue
\$75M

EBITDA
\$18.75M

OpEx
\$41.25M

Year 2
140 people

Revenue
\$93.75M

EBITDA
\$23.4M

OpEx
\$51.6M

Year 3
187 people


Genetic Innovation for Industrial Agriculture

Industrial Hemp

This vertical is focused on industrial-scale agriculture, with Endless developing high-yield, resilient hemp genetics tailored for mass adoption across textiles, construction, and sustainable consumer goods. By applying biotech precision to hemp—a notoriously inconsistent crop—Endless aims to bring stability and scalability to the broader Big Ag supply chain.

The company’s strategy is to become the primary supplier of elite hemp genetics for large-scale growers and processors, replacing traditional seed stock with clean, replicable, performance-optimized cultivars.

- Proprietary high-yield industrial hemp genetics
- Engineered for large-scale cultivation and processing
- Designed for high-performance across multiple industrial applications



- EBITDA margin: 25%
- OpEx = 50% of Revenue
- Headcount CAGR: +20% YoY

Revenue
\$150M

EBITDA

\$37.5M

OpEx

\$75M

Year 1

 30 people

Revenue
\$187.5M

EBITDA

\$46.88M

OpEx

\$93.75M

Year 2

 36 people

Revenue
\$234.4M

EBITDA

\$58.6M

OpEx

\$117.2M

Year 3

 43 people

Consistent Beauty at Commercial Scale

Ornamentals

This vertical targets the high-margin, high-volume world of decorative plant production. Endless applies tissue culture to deliver uniform, disease-free ornamentals at scale—solving the inconsistency, fragility, and inefficiency that have long plagued commercial nurseries and distributors.

By providing predictable, contract-grown ornamentals, Endless helps distributors minimize shrink, improve delivery timelines, and meet demand with absolute consistency—something traditional seed-based production struggles to achieve.

- Tissue culture propagation for large-scale ornamental production
- Uniform, disease-free plant output with high germination success
- Scalable contracts for nurseries and regional distributors




\$1.1B 2%

\$2.2B 4%

\$3.8B 7%

Target Capture

Ornamentals is slated for Year 4 launch, leveraging infrastructure and learnings from our Cannabis and Hemp scale-up. This Phase II vertical taps into a \$127B ornamental plant market with biotech-enabled consistency.




Seed Innovation for a Growing Nation

India Germination

This vertical targets India’s vast soybean and wheat markets, where low germination rates and unreliable seed stock create persistent inefficiencies. Endless is partnering with agricultural stakeholders to introduce biotech-enhanced seeds and tissue culture techniques designed to dramatically increase yield, consistency, and resilience in Indian climates.

By deploying optimized seed genetics and scalable propagation systems, Endless aims to modernize India’s seed infrastructure—starting with two of the country’s most critical staple crops.

- Biotech-augmented seed protocols for soybean and wheat
- Strategic entry into India’s agri-modernization efforts
- Designed to boost germination success and yield at scale



- EBITDA margin: 25%
- OpEx = 45% of Revenue
- Headcount CAGR: +20% YoY

Revenue
\$300M

EBITDA
\$75M

OpEx
\$135M

Year 1

40 people

Revenue
\$375M

EBITDA
\$93.75M

OpEx
\$168.75M

Year 2

48 people

Revenue
\$468.75M

EBITDA
\$117.2M

OpEx
\$210.94M

Year 3

57 people


Turning Expertise Into Scalable Education




Education

The Education vertical transforms Endless’ proprietary knowledge, systems, and biotech insights into a digital platform built for growers, lab operators, and industry professionals. From genetics to germination, the platform offers modular learning designed to elevate skill, standardize practices, and accelerate global adoption of precision cultivation.

Unlike infrastructure-heavy verticals, Education scales without physical barriers. It’s built to deliver global reach with minimal overhead—creating a high-margin, always-on channel for monetizing Endless’ intellectual capital.

- Modular education platform for biotech cultivation and propagation
- Targeted content for growers, labs, and operational leads
- Built to scale globally with low overhead, high margin, and recurring revenue



 **15 people** 18 people

 **21 people**

Vertical	Addressable TAM	Growth TAM	Target Growth Capture	Projected Revenue
Cannabis ¹	\$174B	\$65B	2%	~\$1.3B
Industrial Hemp ²	\$48B	\$10B	2%	~\$200M
Ornamentals ³	\$127B	\$54B	2%	~\$1.1B
India Germination ⁴	–	\$30B+	1%	~\$300M
Education ⁵	\$46B	\$4B	5%	~\$200M

¹ [New Frontier Data](#), [BDSA](#), [Statista](#), and [Grand View Research](#)

² [Markets and Markets](#), [Brightfield Group](#), and [USDA projections](#)

³ [IBIS World](#), [USDA Floriculture Reports](#), and [Statista](#)

⁴ [USDA Foreign Ag Service](#), [India's Ministry of Agriculture](#), [IMARC](#), and [McKinsey India Agri Reports](#)

⁵ [HolonIQ](#), [Global Market Insights](#), and [EdTech Market Reports](#)



- Average EBITDA Margin: 25%
- Average OpEx: ~49% of Revenue
- Average Headcount CAGR: ~+20% YoY

Revenue
\$558M

EBITDA
\$139.5M

OpEx
\$271.8M

Year 1

 180 people

Revenue
\$697.5M

EBITDA
\$174.4M

OpEx
\$339.8M

Year 2

 242 people

Revenue
\$871.9M

EBITDA
\$223.4M

OpEx
\$424.7M

Year 3

 308 people